World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Minghui’s MHB088C will soon start phase 3 in China.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.